Differential diagnosis of leukocytosis and leukopenia
Authors:
Tomáš Arpáš 1; Michael Doubek 1
Authors‘ workplace:
Interní hematologická a onkologická klinika, LF MU a FN Brno
1
Published in:
Vnitř Lék 2022; 68(E-7): 28-35
Category:
Differential Diagnosis Column or What You Can Be Asked at a Postgraduate Certification Exam
doi:
https://doi.org/10.36290/vnl.2022.103
Overview
The blood cell count is often examined in routine clinical praxis. Physiologic leucocyte count is in range 4–10 × 109 in liter of blood. Abnormal values of leukocytes and subtypes of leukocytes in differential count are often present. Changes in leukocytes counts are caused by variety of benignant or malignant conditions. It is important in clinical praxis to interpret changes in blood cell count correctly and choose adequate approach in investigation process. In general, leukocytosis and leukocytopenia may present in primary hematologic disorder or secondary/reactive states, caused by reaction of hematopoiesis to underlying condition. This article review common causes of leukocytosis or leucopenia and give basic advice how to investigate patients with changes in leukocytes count.
Keywords:
differential blood cell count – leukemia – leukocytosis – leukopenia
Sources
1. Chabot‑Richrds DS, George TI. Leukocytosis. Int J Lab Hem. 2014;36,279-288.
2. Hillman RS et al. Heamatolgy in clinical practice, 5. edition, McGraw‑Hill: 2010. ISBN 978-0-07-176653-1
3. Doubek M, Mayer J et al. Léčebné postupy v hematologii 2020. Doporučení ČHS ČLS JEP. ČLS JEP: 2020. ISBN 978-80-270-8240-7
4. Feriel J, Depasse F et al. How I investigate basophilia in daily practice. Int J Lab Hematol. 2020;42:237-245.
5. Larsen R.L., Savage N.M. How I investigate Eosinophilia. Int J Lab Hem. 2019;41:153-161.
6. Novotný J. Hypereozinofilie. Transfuze a hematologie dnes 2021; 27(4):278-282.
7. Lynch DT et al. How I investigate monocytosis. Int J Lab Hem. 2018;40:107-114.
8. Stiene‑Martin A. Nonmalignant Leukocyte Disorders. In: Rodak BF et al. Hematology: Clinical Principles and Aplications (4th edn.). St. Louise. Elsevier: 2012. 408-426. ISBN 978-1-4377-0692-5
9. Guglielmelli P, Vannucchi AM. Current management strategies for polycytemie vera and essential thrombocythemia, Blood Reviews 2020; (42) 100714. ISSN 0268-960X. https:// doi.org/10.1016/j.blre.2020.100714.
10. Patnaik, MM, Tefferi, A. Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95:97-115.
11. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020; 95(6):691-709.
12. Smolej L,Špaček M, Pospíšilová Š et al. Doporučení pro diagnostiku a léčbu chronické lymfocytární leukemie 2021. Transfuze a kematologie dnes 2021;27(1):91-106.
13. Döhner H, Estey E et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129(4):424–447.
14. Terwilliger T, Abdul‑Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer Journal 2017; (7), e577; doi:10.1038/bcj.2017.53
15. Narayanan D., Weinberg O.K. How I investigate acute myeloid leukemia, Int J Lab Hematol. 2020;42:3-15.
16. Frater JL. How I investigate neutropenie, Int J Lab hematol. 2020;42(Suppl. 1):121-132.
17. Staňo Kozubík K,Vrzalová Z et al. Kongenitální neutropenie u dětí a dospělých, Transfuze a hematologie dnes 2021;27(4):297-303.
18. Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129(11):1428-1436.
19. Garcia‑Manero G, Chien KS, Montalban‑Bravo G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95:1399-1420.
20. Doporučení ČHS ČLS JEP, Referenční meze krevního obrazu, retikulocytů, normoblastů a diferenciálního počtu leukocytů dospělých, verze: 2., revize: 2., platnost od: 18. 6. 2021
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2022 Issue E-7
Most read in this issue
- Differential diagnosis of leukocytosis and leukopenia
- Inflammatory markers in clinical practice
- Pegvisomant in the treatment of acromegaly
- Podiatric care from diabetologists point of view